Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Marstacimab

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pfizer`s Biologic Hympavzi (Marstacimab-hncq) Receives Approval in US
    Pfizer`s Biologic Hympavzi (Marstacimab-hncq) Receives Approval in US

    11 Oct 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761369

    FDA
    11 Oct 2024
    Share Share
    FDA and EMA Accept Marstacimab Regulatory Submissions for Hemophilia A and B
    FDA and EMA Accept Marstacimab Regulatory Submissions for Hemophilia A and B

    11 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231211991010/en

    BUSINESSWIRE
    11 Dec 2023
    Share Share
    Pfizer presents marstacimab Phase 3 Data at ASH 2023
    Pfizer presents marstacimab Phase 3 Data at ASH 2023

    10 Dec 2023

    // INDIAN PHARMA POST

    https://www.indianpharmapost.com/news/pfizer-presents-marstacimab-phase-3-data-at-ash-2023-14994

    INDIAN PHARMA POST
    10 Dec 2023
    Share Share
    Marstacimab Phase 3 Data Presented Showes Bleed Reduction in Hemophilia A and B
    Marstacimab Phase 3 Data Presented Showes Bleed Reduction in Hemophilia A and B

    09 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231209134253/en

    BUSINESSWIRE
    09 Dec 2023
    Share Share
    Pfizer Announces +VE Marstacimab Results from Pivotal Ph3 Hemophilia A & B Trial
    Pfizer Announces +VE Marstacimab Results from Pivotal Ph3 Hemophilia A & B Trial

    30 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230530005109/en

    BUSINESSWIRE
    30 May 2023
    Share Share